Doctor in scrubs

W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
13,590 pages, 4,139,114 edits & 37,811,477 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

== Information about Olaratumab ==Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent used in the therapy of advanced soft tissue sarcoma

Liver safety of Olaratumab

Olaratumab has not been linked to serum enzyme elevations during therapy or to idiosyncratic acute liver injury

Mechanism of action of Olaratumab

Olaratumab (oh" lar at' ue mab) is a recombinant human monoclonal IgG1 antibody to the platelet-derived growth factor receptor alpha.  Signaling through PDGF receptors promotes cell proliferation and angiogenesis.  Inhibition of the PDGF signaling decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells.  When used in combination with other antineoplastic agents, olaratumab has been shown to extend recurrence-free survival in several forms of advanced cancer. 

FDA approval information for Olaratumab

Olaratumab was approved in the United States in 2016 for use in combination with doxorubicin for refractory, advanced soft tissue sarcoma

Dosage and administration for Olaratumab

Olaratumab is available in solution in single use vials of 500 mg in 50 mL or 190 mg in 19 mL (10 mg/mL) under the brand name Lartruvo.  The typical dose is 15 mg/kg intravenously over 60 minutes on days 1 and 8 of each 21-day cycle.  Premedication with diphenhydramine and dexamethasone is recommended with the initial dose. 

Side effects of Olaratumab

Olaratumab is administered with doxorubicin and this combination has significant adverse side effects, including nausea and vomiting, diarrhea, fatigue, anorexia, abdominal pain, alopecia, peripheral neuropathy, neutropenia, and stomatitis.  Uncommon, but potentially severe adverse events include severe infusion reactions, hypersensitivity reactions, and embryofetal toxicity.    Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Olaratumab

Reviews for Olaratumab

Learn more about Olaratumab

Latest research - Olaratumab

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Olaratumab is a stub. If you are familiar with the topic Olaratumab, you can help us. Paid editors welcome!


Olaratumab is part of WikiMD's free ^articles!

^Olaratumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available